Skip to Main Content

A Dose Ranging Study Evaluating Efficacy and Safety of NI-03

Conditions

Diseases of the Digestive System - Pancreas | Diseases of the Endocrine System

Phase I-II

What is the purpose of this trial?

The purpose of this study is to determine the safety and efficacy of NI-03.

  • Trial with
    Stason Pharmaceuticals, Inc.
  • Start Date
    02/29/2020
  • End Date
    07/30/2018
Trial Image

For more information about this study, contact:

Christina Rose

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    04/20/2020
  • Study HIC
    #2000023420